Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: GSK3536820A; MCV4 vaccine; MenACWY-CRM; Menveo; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline; Novartis; Tianjin CanSino Biotechnology
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 11 Jun 2019 GlaxoSmithKline completes a phase II trial in Meningococcal infections (Prevention) in Australia, Belgium, Canada, Estonia, Germany, Italy (IM) (NCT03652610)
  • 10 Jun 2019 GlaxoSmithKline initiates a phase II trial in Meningococcal infections (Prevention) in Australia and Italy (IM) before June 2019 (NCT03652610)
  • 10 Sep 2018 GlaxoSmithKline Biologicals initiates a phase II trial in Meningococcal infections (Prevention) in Germany, Belgium, Canada (IM) (EudraCT2017-003692-61) (NCT03652610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top